Epstein-barr Virus Infection
📧 Sign up to get email alerts when something new happens for Epstein-barr Virus Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-22Clinical Trial Results: Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults [Phase 1]
Phase 1 trial evaluating safety and immunogenicity of an Epstein-Barr Virus gp350-Ferritin nanoparticle vaccine in healthy adults has comple…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
This clinical trial studies the natural history of severe viral infections and characterizes immune defects in patients without known immuno…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons [Phase 1, Phase 2]
This trial update reports on the immunogenicity and safety of an adjuvanted Epstein-Barr virus glycoprotein 350 vaccine evaluated in EBV-ser…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
A longitudinal clinical trial sponsored by Sanofi Pasteur studies Epstein-Barr virus (EBV) reactivation in healthy adults ages 18 to 29, wit…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas [Phase 2]
Phase 2 clinical trial evaluating nivolumab in Epstein-Barr virus–positive lymphoproliferative disorders and EBV-positive non-Hodgkin lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection [Phase 1]
A Phase 1 trial is evaluating an Epstein-Barr virus ferritin nanoparticle vaccine (gH/gL/gp42 with or without gp350) in healthy adults, and …
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age [Phase 1]
Phase 1 clinical trial update for an Epstein-Barr virus vaccine candidate, mRNA-1189, currently recruiting in healthy adults.
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation [EARLY_Phase 1]
An early Phase 1 study assessing donor-derived EBV-specific T cells to prevent Epstein-Barr virus infection after allogeneic hematopoietic s…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating EBV-AST cell therapy for Epstein-Barr virus-related diseases after stem cell transplantation, currentl…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Prevalence of Epstein-Barr Virus Infection
This clinical trial update reports on the prevalence of Epstein-Barr virus infection, using lymph node biopsy samples, with the study curren…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]
This clinical trial update describes an exploratory study of EBV-TCR-T cell therapy to treat EBV DNAemia after allogeneic hematopoietic stem…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors [Phase 2]
Phase 2 study evaluating the safety and tolerability of an IDO-1 inhibitor to prevent EBV-related pathology in EBV-negative kidney transplan…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study [NA]
A single-center randomized pilot study comparing valacyclovir versus valganciclovir for CMV and EBV prophylaxis in kidney transplant recipie…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Zuberitamab for EBV Infection Post-Allo-HSCT [Phase 2]
Phase 2 clinical trial of Zuberitamab for Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation; the study i…
-
CLINICAL_TRIALS trial_result · 2025-12-01Clinical Trial Update: Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS Patients
This completed clinical trial investigates environmental risk factors for developing multiple sclerosis in radiologically isolated syndrome …
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
EVITA is a completed study monitoring Epstein-Barr virus infection in renal transplant recipients; the snippet does not include trial result…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) [Phase 1]
Phase Ib study of VK-2019 in patients with EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL). The trial is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants [Phase 1]
A Phase 1 clinical trial update for the Epstein-Barr virus vaccine candidate mRNA-1195 in healthy adults shows the study is active but not r…
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. [Phase 1, Phase 2]
A Phase 1/Phase 2 trial is planned to evaluate a combination of PD-1 inhibitors with Tenofovir, Chidamide, and Lenalidomide for Epstein-Barr…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating virus-specific T-lymphocytes to treat infections with adenovirus, cytomegalovirus, and Epstein-Barr…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. [Phase 1]
Phase 1 clinical trial evaluating TETRAVI Multivirus CTLs to treat EBV, CMV, adenovirus, and BK virus infections in patients after allogenei…
-
CLINICAL_TRIALS other · 2025-08-05Clinical Trial Update: TETRAVI Expanded Access Program
This is an update on the TETRAVI Expanded Access Program sponsored by Baylor College of Medicine, covering viral infections including Epstei…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: R-MVST Cells for Treatment of Viral Infections in Children and Young Adults [Phase 1]
Phase 1 trial evaluating R-MVST Cells for treatment of viral infections in children and young adults is currently recruiting, assessing safe…
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection [Phase 1]
Phase 1 trial assessing safety and immunogenicity of an Epstein-Barr virus gp350-Ferritin nanoparticle vaccine in healthy adults with or wit…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Administration of Donor T Cells With the Caspase-9 Suicide Gene [Phase 1]
A Phase 1 trial evaluating donor T cells engineered with a caspase-9 suicide gene to enable controlled safety in hematologic diseases.